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ABSTRACT

The present disclosure relates to compositions and methods
for treating retinal damage and/or retinal degradation. More
specifically, this disclosure relates to methods for treating
degradation of the retinal pigment epithelium by administering compositions comprising a nucleoside and/or a
nucleoside or nucleotide reverse transcriptase inhibitor.
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COMPOSITIONS AND METHODS FOR
TREATING RETINAL DEGRADATION

to other embodiments of the presently-disclosed subject
matter, whether listed in this summary or not. To avoid
excessive repetition, this summary does not list or suggest
all possible combinations of features.

CROSS-REFERENCE TO RELATED
APPLICATIONS
This application is a continuation of U.S. patent application Ser. No. 15/142,087, filed Apr. 29, 2016, now U.S. Pat.
No. 10,300,057, issued May 28, 2019, which is a continuation of U.S. patent application Ser. No. 14/450,000, filed
Aug. 1, 2014, now U.S. Pat. No. 9,326,983, issued May 3,
2016, which claims the benefit of U.S. Provisional Patent
Application Ser. No. 61/861,290, filed Aug. 1, 2013, and
U.S. Provisional Patent Application Ser. No. 61/987,612,
filed May 2, 2014, the entire disclosures of which are
incorporated herein by this reference.

10

The present disclosure provides, in certain embodiments,
a method for treating retinal damage and/or degradation,
comprising administering an effective amount of a composition to a subject in need thereof, wherein the composition
comprises a reverse transcriptase inhibitor, such as a nucleoside reverse transcriptase inhibitor (NRTI), selected from: (i)
a compound having the structure of

15

TECHNICAL FIELD
The presently-disclosed subject matter relates to compositions for treating retinal damage and/or degradation. More
specifically, this disclosure relates to methods for treating
degradation of the retinal pigment epithelium by administering compositions comprising a nucleoside and/or a
nucleoside reverse transcriptase inhibitor (NRTI).

20

25

BACKGROUND
Geographic atrophy, an advanced form of age-related
macular degeneration that causes blindness in millions of
people worldwide and for which there is no approved
treatment, results from death of retinal pigmented epithelium (RPE) cells. For example, expression of DICER, an
enzyme involved in microRNA (miRNA) biogenesis, is
reduced in the RPE of human eyes with geographic atrophy,
and that conditional ablation of Dicer! induces RPE degeneration in mice. Surprisingly, ablation of seven other
enzymes responsible for miRNA biogenesis or function does
not induce such pathology. Instead, knockdown ofDICERl
leads to accumulation of Alu repeat RNA in human RPE
cells and of Bl and B2 (Alu-like elements) repeat RNAs in
the RPE of mice. Alu RNA is dramatically increased in the
RPE of human eyes with geographic atrophy, and introduction of this pathological RNA induces death of human RPE
cells and RPE degeneration in mice.
Age-related macular degeneration (AMD), which is as
prevalent as cancer in industrialized countries, is a leading
cause of blindness worldwide. In contrast to the neovascular
form of AMD, for which many approved treatments exist,
the far more common atrophic form of AMD remains poorly
understood and without effective clinical intervention.
Extensive atrophy of the retinal pigment epithelium leads to
severe vision loss and is termed geographic atrophy.
Hence, there remains a need for compositions and methods for treating retinal degradation, and particularly RPE
degradation.
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(ii) a compound having the structure of
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BRIEF SUMMARY
This summary describes several embodiments of the
presently-disclosed subject matter, and in many cases lists
variations and permutations of these embodiments. This
s=ary is merely exemplary of the numerous and varied
embodiments. Mention of one or more representative features of a given embodiment is likewise exemplary. Such an
embodiment can typically exist with or without the
feature(s) mentioned; likewise, those features can be applied

or a pharmaceutically acceptable salt thereof;
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or a pharmaceutically acceptable salt thereof; (iii) stavudine
(d4T); (iv) lamivudine (3TC); (v) cordycepin; (vi) azidothymidine (AZT); (vii) abacavir (ABC); and/or (viii) a
combination thereof.
Moreover, the methods of the present disclosure may
further comprise the steps of (i) inhibiting inflanimasome
activation by Alu RNA; (ii) reducing ATP-induced permeability of a cell; (iii) reducing an amount of mitochondria
(reactive oxygen species in a cell; and/or (iv) inhibiting
activation of at least one inflammasome in a subject's eye.
Additionally, the cell(s) of the methods of the present
disclosure may be chosen, for example, from a retinal
pigmented epithelium cell, a retinal photoreceptor cell, a
choroidal cell, and a combination thereof. And an inflammasome of the present disclosure may be, for example, an
NLRP3 inflammasome, an IL-1 beta inflammasome, or a
combination thereof.
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Furthermore, in some embodiments, the present disclosure provides a compound having the structure:

compared to control antisense oligonucleotides (Ctr as) (lane
1 (leftmost)), and co-administration of d4T (lanes 2 and 4)
does not reduce Alu RNA levels. u6 (bottom row) is shown
as a loading control for nuclear fraction.
FIG. 4 provides another example of the results of Northern blotting using an Alu-specific probe. As presented in
FIG. 4, co-administration of d4T does not change Alu RNA
levels at 1, 4, or 24 hours after transfection in the nuclear
fraction of human RPE cells transfected with Alu RNA, with
or without d4T, as detected by Northern blotting using an
Alu-specific probe. u6 (bottom row) is shown as loading
control for nuclear fraction in FIG. 4.
FIG. 5 provides the results of a Western blot showing that
Alu RNA causes Caspase-1 maturation in primary human
RPE cells at 24 hours after Alu administration (top, middle
lane, lower band), which is blocked by co-treatment with
d4T (100 uM; rightmost lane). The bottom row is a vinculin
loading control.
FIG. 6 is a Western blot showing that Alu RNA causes
Caspase-1 maturation in primary human RPE cells at 24
hours after Alu administration (top, middle lane, lower
band), which is blocked with co-treatment with 3 TC (20-100
uM; rightmost lane), wherein the lowermost band is the
loading control, vinculin.
FIG. 7 is a Western blot showing that Alu RNA causes
Caspase-1 maturation in primary human RPE cells at 24
hours after Alu administration (top, middle lane, lower
band), which is blocked with co-treatment with azidothymidine (AZT), cordycepin, and abacavir (ABC) (50-100
uM; lanes 3-8 from left). The loading control vinculin is
shown on the bottom.
FIG. 8 provides a gel showing that primary human RPE
cells treated with LPS/ATP, a classic inflammasome activator, exhibit increased Casp-1 activation, and phosphorylation of IRAK4, which is also a marker of inflanimasome
signaling via the cell surface receptor adaptor protein
MyD88. Moreover, as shown in FIG. 8, d4T (25/100 uM)
blocks Casp-1 activation and IRAK4 phosphorylation
induced by LPS/ATP. Vinculin was used as the loading
control in the gel of FIG. 8. Additionally, as shown, LPS and
ATP activate the NLRP3 inflammasome only in combination.
FIG. 9 provides the results of Western blotting, wherein
d4T, 3TC, and cordycepin (at 100 uM), all di-deoxy nucleoside reverse transcriptase inhibitors, are shown to inhibit
Caspase-1 activation (active p20 band, top) and IL-18 maturation (bottom) induced by LPS/ATP. To produce FIG. 9,
cell culture supernatants were collected after (i) no treatment, (ii) LPS treatment, or (iii) LPS/ATP treatment of
mouse bone marrow-derived macrophages and run on Western blotting probing with antibodies for Caspase-1 and
IL-18.
FIG. 10 provides the result of a Western blot showing that
d4T (100, 250 uM) inhibits IL-1 beta maturation (top, 18 and
22 kDa forms) and Caspase-1 activation (active p20 band,
bottom) induced by nigericin. To produce FIG. 10, cell
culture supernatants were collected after (i) no treatment, (ii)
LPS treatment, or (iii) LPS/nigericin treatment of mouse
bone marrow-derived macrophages and run on Western
blotting probing with antibodies for IL-1 beta and Caspase-
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or a pharmaceutically acceptable salt thereof;
or a compound having the structure
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or a pharmaceutically acceptable sale thereof.
The present disclosure also provides a pharmaceutical
composition comprising at least one of the compounds
provided in the present disclosure, together with a pharmaceutically acceptable carrier. And further embodiments of
the present disclosure include a method for synthesizing at
least one compound provided in the present disclosure.
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BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 displays a top row of ocular fundus photographs of
mice receiving control PBS, or Alu RNA treatment, with or
without increasing amounts of d4T (left to right); and RPE
flat mounts, stained for intercellular junctions (ZO-1) in red
that are disrupted upon Alu RNA administration but that are
restored to healthy RPE morphology/intercellular junctions
at highest dose of d4T.
FIG. 2 provides a bar graph showing that human (HeLa)
cells treated with an enforced expression plasmid for Alu
RNA (pAluA) for denoted amounts of time exhibited profoundly reduced viability compared to a null plasmid
(pUC19), as monitored by MTS proliferation assay and that
d4T co-administration prevented cell death induced by Alu
overexpression.
FIG. 3 shows the results of Northern blotting using an
Alu-specific probe. As presented in FIG. 3, primary human
RPE cells treated with antisense oligonucleotides targeting
DICER! (Der as) (lane 3 (third lane from left)) show
increased Alu RNA levels in the nuclear compartment
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FIG. 11 shows a bar graph illustrating that d4T does not
inhibit IL-1 beta secretion from PMA-differentiated THP-1
monocytes induced by monosodium urate (MSU). FIG. 11
was created after human THP-1 monocytes were differentiated into macrophages with PMA, and, as shown in FIG.
11, treatment with MSU, a known inflammasome activator,
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increased IL-1 beta secretion compared to non-treated cells,
whereas d4T co-administration at a range of doses (25-1000
uM) did not significantly affect IL-1 beta secretion.
FIG. 12 is a bar graph, which shows that d4T and other
nucleoside reverse transcriptase inhibitors do not inhibit
IL-1 beta secretion from PMA-differentiated THP-1 monocytes induced by MSU. Human THP-1 monocytes were
differentiated into macrophages with PMA. Their treatment
with MSU increased IL-1 beta secretion compared to nontreated cells, as shown in FIG. 12, while co-administration
of d4T, 3TC, or cordycepin (all are di-deoxy nucleotide
analogs) at a range of doses (25-1000 uM) did not significantly affect IL-1 beta secretion.
FIG. 13 is a graph, which provides that d4T reduces
NLRP3 priming induced by Alu RNA. Indeed, as shown in
FIG. 13, Alu RNA transfection increases NLRP3 mRNA
levels in primary human RPE cells at 16 hours, an event
termed "priming" (Y-axis) compared to mock (transfection
reagent alone). This effect is blunted by co-administration of
d4T (100 uM) and normalized to 18S RNA control.
FIG. 14 illustrates, in graph format, that Alu RNA transfection increases IL-1 beta mRNA levels in primary human
RPE cells at 24 hours, an event termed "priming", (Y-axis)
compared to mock (transfection reagent alone). This effect is
blunted by co-administration of d4T (100 uM) and normalized to 1SS RNA control.
FIG. 15 shows that d4T reduces mitochondrial ROS
caused by Alu expression. Indeed, FIG. 15 demonstrates that
enforced expression of Alu (pAluA) causes increased mitochondrial reactive oxygen species (mtROS), as detected by
MitoSox assay. In order to produce FIG. 15, primary human
RPE cells were incubated with Alu expressing plasmid or
control plasmid (pUC19) with or without d4T. After 15
hours cells were co-stained for mtROS (red) and for cell
count, nuclei (blue; Hoechst DNA stain). Cells in the pAluA
group exhibited greater mtROS staining (red) compared to
pUC19 control, an effect that is reduced in pAluA+d4T
treated cells.
FIG. 16 provides a graph showing that d4T does not
inhibit ATP release induced by Alu RNA. Moreover, primary
human RPE cells treated with Alu RNA, for the times
indicated in FIG. 16, release ATP. Cell culture supernatant
was collected from mock or Alu RNA treated cells, with or
without d4 T, and ATP was detected using an ATP-dependent
luciferase assay. Notably, d4T did not affect ATP release.
FIG. 17 shows that d4T reduces ATP-induced cell permeability to Yo-Prol (P2X7 receptor assay). Indeed, d4T
dose-dependently reduced Yo-Pro entry induced by ATP,
determined by an area-scan fluorescent measurement in a 96
well microplate reader. FIG. 17 provides the results of the
fluorescence measurement in relative fluorescence units
(RFU, y-axis).
FIG. 18 illustrates, in graph format, that d4T reduces
extracellular potassium levels, which increase after Alu
RNA transfection. Indeed, cell culture potassium levels
increase in primary human RPE cells treated with Alu RNA
for 6 hours, an effect that is reduced by d4T co-administration. Potassium levels were determined in cell culture supernatants spectrophotometrically using a potassium-dependent
pyruvate kinase assay.
FIG. 19 shows that d4T blocks bzATP-induced cell permeability to Yo-Prol (P2X7 receptor assay). To prepare FIG.
19, d4T blocked YO-PRO-1 iodide entry in HEK293 cells
stably expressing the human P2X7 receptor stimulated with
the P2X7-selective agonist bzATP. Cells were pre-incubated
with d4T for 30 minutes prior to addition of bzATP/YO-

PRO, and fluorescence (in relative fluorescence units) at
485/515 nm was measured at t=30 minutes.
FIG. 20 provides a chemical structure of methoxy-d4T
(me-d4T). More specifically, as shown in FIG. 20, a single
substitution of the ribose 5' hydroxyl group of d4T with a
methoxy group (circled) has been designed to prevent d4T
phosphorylation
FIG. 21 is a Western blot of Caspase-1 activation (p20
subunit) in primary human RPE cells transfected with Alu
RNA±me-d4T.
FIG. 22 shows cells, wherein unmodified d4T, but not
me-d4 T, blocks replication of a GFP-expressing lentivirus in
HeLa cells.
FIG. 23 provides a graph illustrating that unmodified d4T,
but not me-d4T, reduces mtDNA levels (normalized to
chromosomal DNA exon-intron junction sequence) in primary mouse RPE cells as determined by real-time quantitative PCR. n=4, *p<0.05 by Student's t-test.
FIG. 24 provides flat mounts stained for zonula
occludens-1 (ZO-1; red), bottom row. Degeneration outlined
by blue arrowheads. Representative images of n=4 (B, C, E)
shown. Scale bars, (C): 200 µm; (E): 20 µm
FIG. 25 provides a schematic overview of me-d4T synthesis.
FIG. 26 is an HPLC chromatogram of me-d4T (peak #6)
final product, >97% purity.
FIG. 27 is a lH NMR spectroscopy of me-d4T final
product, wherein the chemical shifts are consistent with the
structure of me-d4T.
FIG. 28 provides the results of liquid chromatography/
mass spectrometry of me-d4T final product, m/z ratio consistent with the structure of me-d4T.
FIG. 29 provides the methoxy variant of a nucleoside
analog. The chemical structure of 3TC (2'3' dideoxycytidine) is shown, wherein the methoxy variation (O-methyl
group) of nucleoside analog is circled.
FIG. 30 provides the methoxy variant of a nucleoside
analog. The chemical structure of AZT (3'-azido-2',3'-dideoxythymidine) is shown, wherein the methoxy variation
(O-methyl group) of nucleoside analog is circled.
FIG. 31 provides the methoxy variant of a nucleoside
analog. The chemical structure of ABC (cyclopropylaminopurinylcyclopentene) is shown, wherein the methoxy
variation (O-methyl group) of nucleoside analog is circled.
FIG. 32 shows a cell permeant variant of d4T (IC-d4T),
where "n" group is equal to 11. Derivatives include cell
permeant variants of3TC, AZT, ABC, where the nucleobase
group (circled) may be replaced, in various embodiments, by
3TC, AZT, ABC, or methoxy-variants of d4T, 3TC, AZT,
ABC (FIG. 29-31), or derivatives thereof.
FIG. 33 provides the structure of an exemplary NRTI
according to the present disclosure.
FIG. 34 is a Western blot of Caspase-1 activation (p20
subunit) and IRAK4 phosphorylation in primary human
RPE cells transfected with Alu RNA±d4T.
FIG. 35 is a Western blot of Caspase-1 activation in
human RPE cells transfected with Alu RNA±NRTis (3TC,
AZT, ABC).
FIG. 36 includes fundus photographs: top row; flat
mounts stained for zonula occludens-1 (ZO-1; red), bottom
row. bars, 50 µm.
FIG. 37 provides fundus photographs: top row; flat
mounts stained for zonula occludens-1 (ZO-1; red), bottom
row. Scale bars, 50 µm.
FIG. 38 illustrates that NRTis block LPS/ATP-induced
inflammasome activation. Specifically, FIG. 38 shows a gel
indicating that d4T blocked Caspase-1.
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FIG. 39 also illustrates that NRTis block LPS/ATPskill in the art after a study of the information provided in
this document. The information provided in this document,
induced inflammasome activation, showing specifically a
and particularly the specific details of the described exemgel indicating that d4T blocked IL-1 beta.
plary embodiments, is provided primarily for clearness of
FIG. 40 presents chromatograms showing that Raji TK+
cells, but not Raji TK- cells, phosphorylate AZT to AZT- 5 understanding and no unnecessary limitations are to be
understood therefrom. In case of conflict, the specification of
triphosphate (AZT-TP) as determined by liquid chromatogthis document, including definitions, will control.
raphy-mass spectrometry (LC-MS).
The presently-disclosed subject matter is illustrated by
FIG. 41 shows that AZT blocks IL-1 beta activation by
specific but non-limiting examples throughout this descripLPS/ATP in both Raji TK- and TK+ cells, as determined by
10 tion. The examples may include compilations of data that are
Western blot of cell lysates.
representative of data gathered at various times during the
FIG. 42 is a bar graph illustrating that d4T does not block
course of development and experimentation related to the
Alu-induced ATP release from primary human RPE cells
present invention(s). Each example is provided by way of
(n=4).
explanation of the present disclosure and is not a limitation
FIG. 43 provides a graph of P2X7-mediated YO-PRO-1
dye uptake (fluorescence) induced by bzATP (100 µM) in 15 thereon. In fact, it will be apparent to those skilled in the art
that various modifications and variations can be made to the
HEK293 cells stably expressing the human P2X7 receptor
teachings of the present disclosure without departing from
was inhibited by d4T and A438079 (64 µM for both drugs).
the scope of the disclosure. For instance, features illustrated
Fluorescence values are baseline subtracted from cells withor described as part of one embodiment can be used with
out bzATP treatment. * bzATP vs. d4T; # bzATP vs.
A438079, p<0.05 by Student-Newman Keuls post-hoc test 20 another embodiment to yield a still further embodiment.
All references to singular characteristics or limitations of
(n=12).
the present disclosure shall include the corresponding plural
FIG. 44 is a Western blot of Caspase-1 activation (p20
characteristic(s) or limitation(s) and vice versa, unless othsubunit) and IRAK4 phosphorylation in primary mouse RPE
erwise specified or clearly implied to the contrary by the
cells transfected with Alu RNA±d4T.
FIG. 45 is a Northern blot of biotin-UTP-labeled Alu 25 context in which the reference is made.
All combinations of method or process steps as used
RNA-transfected primary human RPE cells.
herein can be performed in any order, unless otherwise
FIG. 46 provides LC-MS/MS spectra of AZT-triphosspecified or clearly implied to the contrary by the context in
phate (AZT-TP).
which the referenced combination is made.
FIG. 47 provides LC-MS/MS spectra of AZU-triphos30
While the following terms used herein are believed to be
phate (AZT-TP
well understood by one of ordinary skill in the art, definiFIG. 48 shows the chromatographic separation of Raji
tions are set forth to facilitate explanation of the presentlyTK- cells spiked with AZT-TP with MS spectra (inset) to
disclosed subject matter.
confirm identity of designated peaks.
Unless defined otherwise, all technical and scientific
FIG. 49 shows the chromatographic separation of Raji
TK- cells spiked with AZU-TP with MS spectra (inset) to 35 terms used herein have the same meaning as commonly
understood by one of ordinary skill in the art to which the
confirm identity of designated peaks.
presently-disclosed subject matter belongs. Although any
FIG. 50 is a standard curve of AZT-TP standards (black
methods, devices, and materials similar or equivalent to
circle). As shown, Raji TK+ samples treated with AZT
those described herein can be used in the practice or testing
produced AZT-TP (white triangles), whereas AZT-TP was
40 of the presently-disclosed subject matter, representative
not detectable in Raji TK- cells treated with AZT.
methods, devices, and materials are now described.
FIG. 51 is a Western blot of Caspase-1 activation (p20
Following long-standing patent law convention, the terms
subunit) in primary human RPE cells transfected with Alu
"a", "an", and "the" refer to "one or more" when used in this
RNA, with short peptide (Panxl 10), which blocks P2X7 pore
application, including the claims. Thus, for example, referfunction but not cation flux (vs. scrambled peptide: Scr45 ence to "a fluorophore" includes a plurality of such images,
Panxl 10 ).
and so forth.
FIG. 52 is a Western blot of Caspase-1 activation (p20
Unless otherwise indicated, all numbers expressing quansubunit) in primary human RPE cells transfected with Alu
tities, properties, and so forth used in the specification and
RNA, with calmidazolium (FIG. 32 provides the chemical
claims are to be understood as being modified in all
structure of IC- and EC-d4T used), which blocks P2X7
50 instances by the term "about". Accordingly, unless indicated
cation flux but not pore function.
to the contrary, the numerical parameters set forth in this
FIG. 53 is a Western blot of Caspase-1 activation (p20
specification and claims are approximations that can vary
subunit) in primary human RPE cells transfected with Alu
depending upon the desired properties sought to be obtained
RNA, with cell permeable (IC), cell-impermeable (EC), or
by the presently-disclosed subject matter.
unmodified (no tag) d4T.
As used herein, the term "about," when referring to a
FIG. 54 shows that d4T prevents pAlu-induced mitochon- 55
value or to an amount of mass, weight, time, volume,
drial ROS generation in primary human RPE cells. In FIG.
concentration or percentage is meant to encompass varia54, mitochondrial reactive oxygen species (ROS) were visutions of in some embodiments ±50%, in some embodiments
alized with MitoSox (Red) and cell nuclei with Hoechst
±40%, in some embodiments ±30%, in some embodiments
(Blue).
60 ±20%, in some embodiments ±10%, in some embodiments
DESCRIPTION OF EXEMPLARY
±5%, in some embodiments ±1 %, in some embodiments
EMBODIMENTS
±0.5%, and in some embodiments ±0.1 % from the specified
amount, as such variations are appropriate to perform the
The details of one or more embodiments of the presentlydisclosed method.
As used herein, ranges can be expressed as from "about"
disclosed subject matter are set forth in this document. 65
one particular value, and/or to "about" another particular
Modifications to embodiments described in this document,
and other embodiments, will be evident to those of ordinary
value. It is also understood that there are a number of values
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disclosed herein, and that each value is also herein disclosed
as "about" that particular value in addition to the value itself.
For example, if the value "10" is disclosed, then "about 10"
is also disclosed. It is also understood that each unit between
two particular units are also disclosed. For example, if 10
and 15 are disclosed, then 11, 12, 13, and 14 are also
disclosed.
The term "physiologically functional derivative" means
any pharmaceutically acceptable derivative of a compound
of the present disclosure. For example, an amide or ester of
a compound of formula (I) or of a compound of formula (II),
which upon administration to a subject, particularly a mammal, is capable of providing, either directly or indirectly, a
compound of the present disclosure of an active metabolite
thereof.
The terms "treatment" or "treating" refer to the medical
management of a subject with the intent to cure, ameliorate,
stabilize, or prevent a condition or disorder (e.g., retinal
degradation). This term includes active treatment, that is,
treatment directed specifically toward the improvement of a
condition, and also includes causal treatment, that is, treatment directed toward removal of the cause of the associated
condition. In addition, this term includes palliative treatment, that is, treatment designed for the relief of symptoms
rather than the curing of the condition; preventative treatment, that is, treatment directed to minimizing or partially or
completely inhibiting the development of symptoms or
disorders of the associated condition; and supportive treatment, that is, treatment employed to supplement another
specific therapy directed toward the improvement of the
associated disease, pathological condition, or disorder.
With regard to administering the compound, the term
"administering" refers to any method of providing a composition and/or pharmaceutical composition thereof to a
subject. Such methods are well known to those skilled in the
art and include, but are not limited to, oral administration,
transdermal administration, administration by inhalation,
nasal administration, topical administration, intravaginal
administration, ophthalmic administration, intraaural
administration, intracerebral administration, rectal administration, and parenteral administration, including injectable
such as intravenous administration, intra-arterial administration, intramuscular administration, subcutaneous administration, intravitreous administration, including via intravitreous sustained drug delivery device, intracameral (into
anterior chamber) administration, suprachoroidal injection,
subretinal administration, Subconjunctival injection, subTenon's administration, peribulbar administration, Transscleral drug delivery, administration via topical eye drops,
and the like. Administration can be continuous or intermittent. In various aspects, a preparation can be administered
therapeutically; that is, administered to treat an existing
disease or condition (e.g., exposure to OP compounds). In
further various aspects, a preparation can be administered
prophylactically; that is, administered for prevention of a
disease or condition.
The term "effective amount" refers to an amount that is
sufficient to achieve the desired result or to have an effect on
an undesired condition. For example, a "therapeutically
effective amount" refers to an amount that is sufficient to
achieve the desired therapeutic result or to have an effect on
undesired symptoms, but is generally insufficient to cause
adverse side effects. The specific therapeutically effective
dose level for any particular patient will depend upon a
variety of factors including the disorder being treated and
the severity of the disorder; the specific composition
employed; the age, body weight, general health, sex and diet

of the patient; the time of administration; the route of
administration; the rate of excretion of the specific compound employed; the duration of the treatment; drugs used
in combination or coincidental with the specific compound
employed and like factors well known in the medical arts.
For example, it is well within the skill of the art to start doses
of a compound at levels lower than those required to achieve
the desired therapeutic effect and to gradually increase the
dosage until the desired effect is achieved. If desired, the
effective daily dose can be divided into multiple doses for
purposes of administration. Consequently, single dose compositions can contain such amounts or submultiples thereof
to make up the daily dose. The dosage can be adjusted by the
individual physician in the event of any contraindications.
Dosage can vary, and can be administered in one or more
dose administrations daily, for one or several days. Guidance
can be found in the literature for appropriate dosages for
given classes of pharmaceutical products. In further various
aspects, a preparation can be administered in a "prophylactically effective amount"; that is, an amount effective for
prevention of a disease or condition.
The terms "subject" or "subject in need thereof' refer to
a target of administration, which optionally displays symptoms related to a particular disease, condition, disorder, or
the like. The subject(s) of the herein disclosed methods can
be human or non-human (e.g., primate, horse, pig, rabbit,
dog, sheep, goat, cow, cat, guinea pig, rodent, and nonmammals). The term "subject" does not denote a particular
age or sex. Thus, adult and newborn subjects, as well as
fetuses, whether male or female, are intended to be covered.
The term "subject" includes human and veterinary subjects.
As will be recognized by one of ordinary skill in the art,
the terms "suppression," "suppressing," "suppressor," "inhibition," "inhibiting" or "inhibitor" do not refer to a complete
elimination of angiogenesis in all cases. Rather, the skilled
artisan will understand that the term "suppressing" or
"inhibiting" refers to a reduction or decrease in angiogenesis. Such reduction or decrease can be determined relative
to a control. In some embodiments, the reduction or decrease
relative to a control can be about a 1, 2, 3, 4, 5, 6, 7, 8, 9,
10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,
26, 27,28,29,30, 31,32,33,34, 35,36,37,38, 39,40,41,
42, 43,44,45,46, 47,48,49, 50, 51, 52, 53, 54, 55, 56, 57,
58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73,
74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89,
90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% decrease.
In some exemplary embodiments, the presently-disclosed
subject matter includes methods for treating retinal damage
and/or retinal degeneration. Indeed, some methods of the
present disclosure comprise administering to a subject in
need thereof an effective amount of a composition for
treating retinal damage and/or degradation.
In some embodiments the composition comprises a
nucleoside and/or a nucleoside reverse transcriptase inhibitor (NRTI). Further, in some embodiments, the composition
is a pharmaceutical composition comprising a nucleoside
and/or a NRTI compound as well as a pharmaceutically
acceptable carrier.
As discussed herein, in some exemplary methods of the
present disclosure, the administered composition is a composition comprising a nucleoside and/or NRTI. Thus, exemplary compositions are comprised of compounds including,
but not limited to, stavudine (d4T), lamivudine (3TC),
cordycepin, azidothymidine (AZT), abacavir (ABC), chemical derivatives thereof methoxy-derivatives to abrogate
phosphorylation), and the like. Other possible compounds
include, for example, those described in U.S. Pat. No.
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6,514,979 to Heredia et al. Those of ordinary skill in the art
will also recognize further nucleosides and/or NRTis, as
described herein, that can be used in the compositions and
methods of this disclosure.
In some embodiments a method of the present disclosure
comprises inhibiting activation of one or more physiological
processes by Alu RNA. As disclosed herein, Alu RNA
(including Alu repeat RNA in human cells and Bl and B2,
Alu-like element repeat RNAs) increases are associated with
cells that are associated with certain conditions of interest.
For example, an Alu RNA increase is associated with the
retinal pigment epithelium (RPE) cells of eyes with geographic atrophy. This increase of Alu RNA induces the death
of RPE cells. Methods and compositions disclosed herein
can treat RPE degradation, thereby treating conditions associated with such cell death.
In some embodiments, a method of the present disclosure
comprises inhibiting the activation of at least one inflammasome. In certain embodiments, the at least one inflammasome is selected from an NLRP3 inflammasome, a
IL-1 beta inflammasome, and a combination thereof. In some
embodiments, the inhibiting one or more inflammasomes of
a cell includes administering an inhibitor (composition) to
the cell and/or to a subject, wherein the cell is the cell of a
subject. For compositions comprising an inhibitor, an inhibitor as described herein can be, for example, a polypeptide
inhibitor (including an oligonucleotide inhibitor), a small
molecule inhibitor, and/or an siRNA inhibitor.
Moreover, some exemplary methods of administering the
present composition(s) can inhibit inflammation by LPS/
ATP, inflammasome activation by LPS/ATP, inflammasome
activation by Alu RNA, and/or nigericin-induced inflammasome activation. Exemplary methods can also treat retinal
degradation and/or other retinal damage by reducing mitochondrial reactive oxygen species, particularly as caused by
Alu RNA expression, by blocking entry via the P2X7
receptor, and/or by reducing ATP-induced cell permeability.
In some embodiments, a method of the present disclosure
comprises treating retinal damage by inhibiting a particular
action in a cell. In some embodiments, the cell is selected
from an RPE cell, a retinal photoreceptor cell, or a choroidal
cell. In some embodiments, the cell is an RPE cell. In some
embodiments, the cell is the cell of a subject. In some
embodiments, the cell is a cell of a subject having, suspected
of having, or at risk of having a condition of interest. In some
embodiments, the cell is a cell of a subject having, suspected
of having, or at risk of having age-related macular degeneration. In some embodiments, the cell is a cell of a subject
having, suspected of having, or at risk of having geographic
atrophy. In some embodiments, the cell is a cell of a subject
having, suspected of having, or at risk of having geographic
atrophy and the cell is an RPE cell. In some embodiments,
a subject having age-related macular degeneration can be
treated using methods and compositions as disclosed herein.
Thus, as used herein with reference to a polypeptide being
inhibited, "of a cell" refers to a polypeptide that is inside the
cell (inside the cell membrane), on the cell (in the cell
membrane, presented on the cell membrane, otherwise on
the cell), or outside of a cell, but insofar as the polypeptide
is outside of the cell, it is in the extracellular milieu such that
one of ordinary skill in the art would recognize the polypeptide as being associated with the cell. For example,
VDA Cl, VDAC2, caspase-8, NFKB, or a polypeptide of an
inflammasome (e.g., NLRP3, PYCARD, caspase-1) could
be in the cell. For another example, NLRP3 could be in the
cell or on the cell.

As described herein, the presently-disclosed subject matter further includes pharmaceutical compositions comprising the compounds described herein together with a pharmaceutically acceptable carrier.
The term "pharmaceutically acceptable carrier" refers to
sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just
prior to use. Proper fluidity can be maintained, for example,
by the use of coating materials such as lecithin, by the
maintenance of the required particle size in the case of
dispersions and by the use of surfactants. These compositions can also contain adjuvants such as preservatives,
wetting agents, emulsifying agents and dispersing agents.
Prevention of the action of microorganisms can be ensured
by the inclusion of various antibacterial and antifungal
agents such as paraben, chlorobutanol, phenol, sorbic acid
and the like. It can also be desirable to include isotonic
agents such as sugars, sodium chloride and the like. Prolonged absorption of the injectable pharmaceutical form can
be brought about by the inclusion of agents, such as aluminum monostearate and gelatin, which delay absorption.
Injectable depot forms are made by forming microencapsule
matrices of the drug in biodegradable polymers such as
polylactide-polyglycolide, poly(orthoesters) and poly(anhydrides). Depending upon the ratio of drug to polymer and the
nature of the particular polymer employed, the rate of drug
release can be controlled. Depot injectable formulations are
also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues. The
injectable formulations can be sterilized, for example, by
filtration through a bacterial-retaining filter or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water
or other sterile injectable media just prior to use. Suitable
inert carriers can include sugars such as lactose.
Suitable formulations include aqueous and non-aqueous
sterile injection solutions that can contain antioxidants,
buffers, bacteriostats, bactericidal antibiotics and solutes
that render the formulation isotonic with the bodily fluids of
the intended recipient; and aqueous and non-aqueous sterile
suspensions, which can include suspending agents and
thickening agents.
The compositions can take such forms as suspensions,
solutions or emulsions in oily or aqueous vehicles, and can
contain formulatory agents such as suspending, stabilizing
and/or dispersing agents. Alternatively, the active ingredient
can be in powder form for constitution with a suitable
vehicle, e.g., sterile pyrogen-free water, before use.
The formulations can be presented in unit-dose or multidose containers, for example sealed ampoules and vials, and
can be stored in a frozen or freeze-dried (lyophilized)
condition requiring only the addition of sterile liquid carrier
immediately prior to use.
For oral administration, the compositions can take the
form of, for example, tablets or capsules prepared by a
conventional technique with pharmaceutically acceptable
excipients such as binding agents (e.g., pregelatinized maize
starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or
calcium hydrogen phosphate); lubricants (e.g., magnesium
stearate, talc or silica); disintegrants (e.g., potato starch or
sodium starch glycollate); or wetting agents (e.g., sodium
lauryl sulphate). The tablets can be coated by methods
known in the art.
Liquid preparations for oral administration can take the
form of, for example, solutions, syrups or suspensions, or
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they can be presented as a dry product for constitution with
water or other suitable vehicle before use. Such liquid
preparations can be prepared by conventional techniques
with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or
hydrogenated edible fats); emulsifying agents (e.g. lecithin
or acacia); non-aqueous vehicles (e.g., almond oil, oily
esters, ethyl alcohol or fractionated vegetable oils); and
preservatives (e.g., methyl or propyl-p-hydroxybenzoates or
sorbic acid). The preparations can also contain buffer salts,
flavoring, coloring and sweetening agents as appropriate.
Preparations for oral administration can be suitably formulated to give controlled release of the active compound. For
buccal administration the compositions can take the form of
tablets or lozenges formulated in conventional manner.
The compositions can be formulated as eye drops. For
example, the pharmaceutically acceptable carrier may comprise saline solution or other substances used to formulate
eye drop, optionally with other agents. Thus, eye drop
formulations permit for topical administration directly to the
eye of a subject.
The compositions can also be formulated as a preparation
for implantation or injection. Thus, for example, the compounds can be formulated with suitable polymeric or hydrophobic materials (e.g., as an emulsion in an acceptable oil)
or ion exchange resins, or as sparingly soluble derivatives
(e.g., as a sparingly soluble salt). The compounds can also
be formulated in rectal compositions, creams or lotions, or
transdermal patches.
The presently-disclosed subject matter further includes a
kit that can include a compound or pharmaceutical composition as described herein, packaged together with a device
useful for administration of the compound or composition.
As will be recognized by those or ordinary skill in the art,
the appropriate administration-aiding device will depend on
the formulation of the compound or composition that is
selected and/or the desired administration site. For example,
if the formulation of the compound or composition is
appropriate for injection in a subject, the device could be a
syringe. For another example, if the desired administration
site is cell culture media, the device could be a sterile
pipette.
Moreover, NRTis of the present disclosure are a diverse,
widely used, inexpensive class of small molecules, with
extensive pharmacokinetic and safety data collected over the
past several decades of human use; NRTis are therefore ripe
for drug repurposing. As such, the present disclosure provides a novel and broadly applicable basis for use of one or
more NRTis by addressing major unmet medical needs.
As briefly described above, age-related macular degeneration is a disease that affects tens of millions of people
worldwide, and there is no effective treatment for AMD
(Ambati and Fowler, 2012). Similarly, graft-versus host
disease is the major obstacle preventing successful tissue
transplant (Ferrara et al., 2009); and sterile liver inflammation is a major contributor to drug-induced liver injury and
steatohepatitis, a major determinant of fibrosis and carcinogenesis (Kubes and Mehal, 2012). Thus, some methods
and/or compounds of the present disclosure are intended to
treat age-related macular degeneration, graft-versus host
disease, and/or sterile liver inflammation by administering,
in some embodiments, a compound comprising at least one
NRTI, as provided in the present disclosure.
Since inflammasome inhibition by NRTis can be achieved
without phosphorylation of a particular NRTI, the use of
me-d4T or other phosphorylation-incompetent nucleoside
analogs, as provided herein, should avoid therapeutic-lim-

iting toxicities associated with NRTI-triphosphate-mediated
polymerase inhibition (Lewis et al., 2003). Accordingly, in
some embodiments, the present disclosure is directed to
methods for treating retinal disease by administering
me-d4T or another phosphorylation-incompetent nucleoside
analog to a subject in need thereof.
Further, in certain embodiments, the present disclosure
provides methods for treating retinal damage, comprising:
administering an effective amount of a composition to a
subject in need thereof, wherein the composition comprises
an NRTI. In some embodiments, the NRTI is selected from
the group consisting ofstavudine (d4T), lamivudine (3TC),
cordycepin, azidothymidine (AZT), abacavir (ABC), or
derivatives or combinations thereof.
In some embodiments, the presently disclosed subject
matter provides methods for protecting an RPE cell, a retinal
photoreceptor cell, a choroidal cell, or a combination
thereof, comprising at least the step of administering a
composition that comprises at least one nucleoside analog or
NRTI, according to the present disclosure, to a subject in
need thereof.
Moreover, in some embodiments, the present disclosure is
directed to the synthesis and/or use of one or more compounds of Formula I, Formula II, Formula III, Formula IV,
and/or Formula IV:
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-continued

Pseudomonas aeruginosa, Vibrio cholera, Legionella spp.,
Francisella spp., and Leishmania spp. a Chlamydia spp.,
cryopyrinopathies; keratitis, acne vulgaris, Crohn's disease,
ulcerative colitis, irritable bowel syndrome, insulin resistance, obesity, hemolytic-uremic syndrome, polyoma virus
infection, immune complex renal disease, acute tubular
injury, lupus nephritis, familial cold autoinflammatory syndrome, Muckle-Wells syndrome and neonatal onset multisystem inflammatory disease, chronic infantile neurologic
cutaneous and articular autoinflammatory diseases, renal
ischemia-perfusion injury, glomerulonephritis, cryoglobulinemia, systemic vasculitides, IgA nephropathy, malaria,
helminth parasites, septic shock, allergic asthma, hay fever,
chronic obstructive pulmonary disease, drug-induced lung
inflammation, contact dermatitis, leprosy, Burkholderia
cenocepacia infection, respiratory syncitial virus infection,
psoriasis, scleroderma, reactive arthritis, cystic fibrosis,
syphilis, Sjiigren's syndrome, inflammatory joint disease,
non-alcoholic fatty liver disease, cardiac surgery (peri-/postoperative inflammation), acute and chronic organ transplant
rejection, acute and chronic bone marrow transplant rejection, tumor angiogenesis, and/or any combination thereof.
Moreover, in some embodiments, the present disclosure
provides that non-canonical NRTI function, independent of
chain termination, prevents P2X7-dependent blindness,
graft-versus-host disease and/or sterile inflammation.
Accordingly, the present disclosure is directed, in certain
embodiments, to methods of preventing P2X7-dependent
blindness, graft-versus-host disease and/or inflammation in
a subject by administering an effective amount of at least one
NRTI, as described herein., to subject in need thereof.
Further, in certain embodiments, the methods and compositions of the present disclosure inhibit (i) inflammasome
activation by Alu RNA associated with a cell; (ii) inflammation by LPS/ATP, (iii) inflammasome activation by LPS/
ATP, (iv) nigericin-induced inflammasome activation, and/
or combinations thereof. And in some embodiments, the
inflammasome is selected from the group consisting of a
NLRP3 inflammasome and/or a IL-1 beta inflammasome.
Additionally, some embodiments of the methods of the
present disclosure may include, for example, the steps of (i)
blocking entry via a P2X7 receptor associated with a cell;
(ii) reducing mitochondrial reactive oxygen species caused
by Alu RNA expression; and/or (iii) reducing ATP-induced
cell permeability of a cell. And a cell contemplated in the
present disclosure may include, for example, an RPF: cell,
a retinal photoreceptor cell, a choroidal cell, or any combination thereof.
Further, NRTis are mainstay therapeutics for HIV, and
they block retrovirus replication. Alu RNA, an endogenous
retroelement that also requires reverse transcriptase (RT) for
its life cycle, activates the NLRP3 inflammasome to cause
cell death of the retinal pigment epithelium in geographic
atrophy, which is the untreatable form of age-related macular degeneration that blinds millions of individuals. Moreover, the inventors of the present disclosure have found that
NRTis, as a class, are novel inhibitors of the NLRP3
inflammasome. And, surprisingly, this effect is independent
of reverse transcriptase inhibition.
Thus, the inventors of the present disclosure have found
that the NRTis d4T, AZT, ABC, and 3TC block Caspase 1
activation by Alu RNA, as does 5'-methoxy-d4T, which does
not inhibit reverse transcriptase. Further, the present inventors have found that AZT is not phosphorylated in thymidine
kinase-deficient cells but still blocks LPS/ATP-induced
interleukin-I beta secretion; that NRTis block P2X7-dependent YOPR0-1 dye uptake in mouse models of geographic
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and/or to any salt, particularly any pharmaceutically acceptable salt, any solvate, and/or any physiological derivative
thereof. In some embodiments, "n" of Formula IV is any
integer, and in a particular embodiment, n is 11.
Further, the present disclosure provides uses of a compound of any of Formulas (I), (II), (III), (IV) and/or (IV), or
any combination thereof, in the preparation or manufacture
of a pharmaceutical composition, such as a drug and/or
medicine, especially a composition for the treatment of
retinal damage and/or retinal degeneration in a mammal. In
some embodiments, the present disclosure provides a pharmaceutical composition comprising a compound of any of
Formulas (I), (II), (III), (IV) and/or (IV), any salt, particularly any pharmaceutically acceptable salt, any solvate,
and/or any physiological derivative thereof, together with a
pharmaceutically acceptable carrier.
In certain embodiments, the methods and compositions of
the present disclosure inhibit graft-versus-host disease,
chronic pain, proliferative vitreoretinopathy, glaucoma,
rheumatoid arthritis, multiple sclerosis, bipolar disorder,
major depressive disorder, renal fibrosis, nephritis, pulmonary fibrosis, Huntington's disease, osteoporosis, chronic
lymphocytic leukemia, anxiety disorders, pulmonary tuberculosis, osteoporosis in post-menopausal women and fracture patients, systemic lupus erythematosus, chronic inflammatory and neuropathic pain, autosomal dominant
polycystic kidney disease, spinal cord injury, Alzheimer's
disease, neuropathic pain, hypertension, varicose veins, type
1 diabetes, type II diabetes, gout, autoimmune hepatitis,
graft vascular injury, atherosclerosis, thrombosis, metabolic
syndrome, salivary gland inflammation, traumatic brain
injury, ischemic heart disease, ischemic stroke Parkinson's
disease, melanoma, neuroblastoma, prostate, breast, skin,
and thyroid cancers, tubular early gastric cancer, neuroendocrine cancer, mucoid colon cancer, colon cancer; highgrade urothelial carcinoma, kidney clear cell carcinoma,
undifferentiated ovary carcinoma, papillary intracystic
breast carcinoma, gram negative sepsis, infectious

30

35

40

45

50

55

60

65

US 10,864,212 B2
17

18

atrophy, graft-versus-host disease, and sterile liver inflammation; and that NRTis are novel inhibitors of the NLRP3
inflammasome independent of canonical reverse transcriptase inhibition. Accordingly, NRTis are ripe for drug
repurposing in a variety of P2X7-driven diseases.
NRTis were first discovered to be anti-viral compounds in
1974 (Ostertag et al., 1974), and are widely used to treat
human immunodeficiency virus (HIV). The canonical
mechanism of action of NRTis is via chain termination of
DNA synthesis from a viral RNA template, thereby interfering with the viral life cycle of reverse transcriptasedependent viruses.
Age-related macular degeneration (AMD) is a leading
cause of blindness in the elderly worldwide (Ambati et al.,
2003; Ambati and Fowler, 2012). In the more prevalent and
untreatable dry form of AMD, overabundance of non-coding
Alu RNAs causes blindness by inducing cell death of the
retinal pigment epithelium (Dridi et al., 2012; Kaneko et al.,
2011; Tarallo et al., 2012). Alu sequences are non-coding
retrotransposons that, like HIV, rely on reverse transcriptase
for their life cycle (Batzer and Deininger, 2002; Dewannieux
et al., 2003 ).
Alu RNA mediates RPE cell death via activation of
Caspase 1 and the NLRP3 inflammasome (Tarallo et al.,
2012). The present disclosure provides that a reverse transcriptase inhibitor, such as stavudine (d4T; 2'3' dideoxythymidine; Zerit, Bristol-Myers Squibb), which is FDA-approved for the treatment of HIV, prevents Caspase 1
cleavage to its active 20 kDa form (Hentze et al., 2003;
Yamin et al., 1996) in primary human (FIG. 34) and mouse
RPE cells (FIG. 44) without reducing Alu RNA levels (FIG.
45). Further, the present disclosure shows that d4T also
blocks phosphorylation of IRAK4, a kinase downstream of
the MyD88 adaptor that mediates Alu-induced RPE cell
death (Tarallo et al., 2012), in human and mouse RPE cells
(FIG. 34 and FIG. 44). The inventors of the present disclosure have also found that other NRTis, including the antiHIV drugs azidothymidine (AZT; 3'-azido-2',3'-dideoxythymidine; Retrovir, ViiV Healthcare), lamivudine (3TC; 2'3'
dideoxycytidine; Zeflix, GlaxoSmithKline) and abacavir
(ABC; a di-deoxyguanosine analog; Ziagen, ViiV Healthcare), also block Caspase-1 cleavage induced by Alu RNA
(FIG. 35).
Additionally, the present disclosure provides that d4T and
AZT prevent RPE degeneration in the Alu RNA-induced
mouse model of dry AMD. (Kaneko et al., 2011; Tarallo et
al., 2012) Moreover, it has been found that mice receiving
daily oral administration of d4T blocked RPE degeneration
after sub-retinal injection of a plasmid expressing Alu RNA
(FIG. 36), as did intraperitoneal administration of AZT (FIG.
37).
In order to test whether reverse transcriptase inhibition
was required for inflammasome blockade by d4T, a 5'
O-methyl-modified version of d4T (5'-OCH3-d4T; me-d4T)
was synthesized (FIG. 20; FIG. 25, FIG. 36, FIG. 27, FIG.
28). Accordingly, in some embodiments, the present disclosure is directed to methods for synthesizing a 5' O-methylmodified version of d4T as provided herein.
Only the triphosphate version of nucleoside analogs
inhibit reverse transcriptase; the methyl modification at the
5' position prevents phosphorylation and thus formation of
nucleoside triphosphate (Nykanen et al., 2001). Accordingly, like d4T, me-d4T also blocks Caspase-1 activation in
human RPE cells (FIG. 21).
The present inventors have confirmed that me-d4T does
not inhibit reverse transcriptase: and, in contrast to urnnodified d4T, me-d4T does not block lentivirus replication (FIG.

22). Also, the triphosphate metabolite of di-deoxy nucleoside analogs caused depletion of mitochondrial DNA; and
consistent with the idea that me-d4T is not phosphorylated,
it has been found that d4T, but not me-d4T reduces mtDNA
levels. (FIG. 23). Me-d4T also prevents Alu-induced RPE
degeneration in mice (FIG. 24). These data indicate that d4T
can block Caspase-1 activation and RPE degeneration independent of reverse transcriptase inhibition.
Further, the present inventors also tested whether NRTis
blocked inflammasome activation by LPS/ATP, which is not
known to signal via reverse transcriptase (Mariathasan et al.,
2004; Mariathasan et al., 2006; Martinon et al., 2002). It was
found that d4T inhibited LPS/ATP-induced Caspase-1 maturation in primary mouse bone marrow-derived macrophages
(FIG. 38) as detected by Western blot.
Caspase-1 directly processes interleukin 1 beta (IL-1 beta)
upon LPS/ATP stimulation; d4T also blocks secretion of
mature IL-1 beta in these cells (FIG. 39). To determine
whether LPS/ATP-induced inflammasome activation can be
inhibited without RT inhibition, the present inventors utilized thymidine kinase-deficient (Raji/TK-) and -expressing
(Raji/TK+) cells (Balzarini et al., 1989). After addition of
AZT, TK-, but not TK- cells, the present inventors produced
AZT-triphosphate (AZT-TP), the AZT metabolite required
for RT inhibition (FIG. 40; FIG. 46, FIG. 47, FIG. 48, FIG.
49, FIG. 50). Even though AZT was not phosphorylated in
TK- cells, AZT still inhibited LPS/ATP-induced interleukin-I beta maturation (FIG. 41), indicating that AZT did
not inhibit interleukin-I beta maturation via reverse transcriptase inhibition.
Alu RNA (Kerur et al., 2013) and LPS/ATP (Qu et al.,
2011) activate the inflammasome via the ATP receptor
P2X7. The present inventors therefore hypothesized that
d4T blocks P2X7 or some P2X7-dependent pathway. First,
testing was conducted to determine whether d4T acts
upstream of P2X7 by modulating ATP levels; however, d4T
does not block release of ATP to cell culture media induced
by Alu RNA (FIG. 42).
Next, testing was conducted to determine whether d4T
directly antagonizes P2X7 function: upon ATP binding,
cell-surface P2X7 forms non-selective cation channels that
mediate inflammasome activation (Kahlenberg and Dubyak,
2004; Petrilli et al., 2007). However, d4T did not significantly modulate P2X7 cation charmel function as monitored
by patch clamp analysis of HEK293 stable cell lines
expressing either the human or rat P2X7 receptor (Humphreys et al., 2000).
Finally, P2X7 activation is associated with the formation
of a large pore that is permeable to molecules of up to -1000
Da (Adinolfi et al., 2005; Cheewatrakoolpong et al., 2005;
Surprenant et al., 1996). It was found that d4 T, and also AZT
and 3TC, inhibited P2X7-dependent uptake of the fluorescent dye YO-PRO 1 (M. W. Da) in human P2X7-overexpressing HEK293 stable cell line (FIG. 43) after addition of the
selective P2X7 agonist bzATP.
Consistent with the idea that NRTis block Alu-induced
P2X7-mediated inflammasome activation via a mechanism
involving dye uptake, Alu RNA-induced Caspase-1 activation was inhibited by a small peptide that blocks P2X7mediated dye uptake and LPS/ATP-induced inflarmnasome
activation, but not cation flux (Pelegrin and Surprenant,
2006) (FIG. 51). On the other hand, Alu-induced Caspase-1
activation was not inhibited by calmidazolium, which selectively blocks P2X7-mediated cation flux but not dye uptake
(FIG. 52).
Furthermore, the intracellular C-terminus of P2X7 governs P2X7-associated dye uptake, and a version of d4T that
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is not cell permeable (Agarwal et al., 2011) does not block
caspase-1 activation by Alu RNA (FIG. 53, FIG. 32).
Consistent with antagonism at or downstream of P2X7, but
upstream of mitochondrial dysfunction, d4T blocks mitochondrial ROS (mtROS) production, which are produced
upon LPS/ATP stimulation (Adinolfi et al., 2005; Cruz et al.,
2007; Garcia-Marcos et al., 2005; Nakahira et al., 2011) and
Alu overexpression (Tarallo et al., 2012) was measured by
MitoSOx assay (FIG. 54). Finally, d4T does not prevent
P2X7-independent interleukin I-beta secretion in PMAprimed THP-1 cells treated with crystalline monosodium
urate (FIG. 11) (Martinon et al., 2006; Riteau et al., 2012).
To explore the potential therapeutic relevance of NRTis
beyond the Alu-induced model of geographic atrophy (GA),
it was hypothesized that if NRTis function as generic
inflammasome inhibitors, then they might be broadly useful
in other animal models of disease that are also driven by
P2X7. In the NLRP3 inflammasome- and P2X7-driven
graft-versus-host disease model (Jankovic et al., 2013; Wilhelm et al., 2010), treatment of mice receiving allogeneic
bone marrow and T cells with d4T showed improved survival compared to saline treated controls (30-70% vs. 0%).
Furthermore, in the NLRP3- and P2X7-driven model of
sterile inflammation (McDonald et al., 2010), d4T reduced
neutrophil migration to the focus of liver injury.
Interestingly, it has been shown that P2X7-dependent
pore function alone can influence phenotype (Sorge et al.,
2012). However, at present, there are not any FDA-approved
drugs that selectively target downstream P2X7 signaling and
not ion channel activation. Therefore, NRTis could be
valuable both clinically and experimentally in the selective
targeting of P2X7 function.
A role for P2X7 in regulating HIV replication was
recently proposed (Hazleton et al., 2012), and HIV patients
have increased plasma IL-18 levels (Ahmad et al., 2002;
Iannello et al., 2010), which decrease after treatment with
NRTI-containing highly active anti-retroviral therapy (Stylianou et al., 2003). Notably, reduction of plasma IL-18 levels
by NRTI treatment of HIV-1 infected patients did not
significantly associate with viral load or CD4+ T-cell counts
(David et al., 2000), indicating that NRTis can dampen
IL-18 levels before inhibition of viral replication occurs.
IL-18 maturation requires pro-IL18 cleavage by active
Caspase 1, which typically also requires P2X7 activation.
Thus, the methods and experiments of the present disclosure
are consistent with the idea that NRTis can modulate HIVinduced cytokine expression independent of reverse transcriptase inhibition.
In some embodiments, d4T prevents RPE degeneration
induced by Alu RNA in wild type mice. As shown in FIG.
1, sub-retinal Alu RNA administration to mice causes RPE
degeneration in a mouse model of age-related macular
degeneration. Indeed, as shown, d4T co-delivered to the
vitreous humor of wild type mice prevents Alu RNAinduced RPE cell death in a dose-dependent manner at one
week after delivery. The top row of FIG. 1 provides an
ocular fundus photograph of mice receiving control PBS, or
Alu RNA treatment, with or without increasing amounts of
d4T (left to right). Arrows denote depigmented regions of
RPE cell death, which resolve at highest dose of d4T. The
bottom row of FIG. 1 shows an RPE flat mount, stained for
intercellular junctions (ZO-1) in red that are disrupted upon
Alu RNA administration, but restored to healthy RPE morphology/intercellular junctions at highest dose of d4T.
Meanwhile, in certain embodiments, d4T protects against
cytotoxicity induced by plasmid expressing Alu RNA in
vitro. FIG. 2 shows that human (HeLa) cells treated with an

enforced expression plasmid for Alu RNA (pAluA) for
denoted amounts of time exhibited profoundly reduced
viability compared to a null plasmid (pUC19), as monitored
by MTS proliferation assay, and that d4T co-administration
prevented cell death induced by Alu overexpression.
In some exemplary embodiments, d4T does not rescue
cytotoxicity via reduction in Alu RNA levels. As presented
in FIG. 3, primary human RPE cells treated with antisense
oligonucleotides targeting DICER! (Der as) (lane 3 (third
lane from left)) show increased Alu RNA levels in the
nuclear compartment compared to control antisense oligonucleotides (Ctr as) (lane 1 (leftmost)), monitored by Northern blotting using an Alu-specific probe. Meanwhile, coadministration of d4T (lanes 2 and 4) does not reduce Alu
RNA levels. FIG. 3 shows u6 (bottom row) as a loading
control for nuclear fraction.
Moreover, in some embodiments, d4T does not reduce
Alu RNA levels. For example, primary human RPE cells
may be transfected with Alu RNA, with or without d4T.
(FIG. 4) And, as presented in FIG. 4, co-administration of
d4T does not change Alu RNA levels at 1, 4, or 24 hours
after transfection in the nuclear fraction, as detected by
Northern blotting using an Alu-specific probe. U6 (bottom
row) is shown as loading control for nuclear fraction in FIG.
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The present disclosure further provides that, in some
embodiments, d4T inhibits inflanmiasome activation by Alu
RNA. Indeed, Alu RNA causes NLRP3 inflammasome activation, which is marked by processing of the enzyme
Caspase 1, and FIG. 5 provides a Western blot showing that
Alu RNA causes Caspase-1 maturation in primary human
RPE cells at 24 hours after Alu administration (Top, Lane 2,
lower band), which is blocked by co-treatment with d4T
(100 uM; Lane 3). The bottom row in FIG. 5 is a vinculin
loading control.
In certain embodiments, 3TC inhibits inflanmiasome activation by Alu RNA. Indeed, Alu RNA causes NLRP3
inflammasome activation, which is marked by processing of
the enzyme Caspase 1. FIG. 6 is a Western blot showing that
Alu RNA causes Caspase-1 maturation in primary human
RPE cells at 24 hours after Alu administration (top, lane 2,
lower band), which is blocked with co-treatment with 3TC
(20-100 uM; lane 3). On the bottom, the loading control,
vinculin, is visible.
Next, FIG. 7 provides evidence of AZT, cordycepin, and
abacavir inhibition of inflammasome activation by Alu
RNA. Indeed, Alu RNA causes NLRP3 inflammasome activation, which is marked by processing of the enzyme
Caspase 1. FIG. 7 is a Western blot showing that Alu RNA
causes Caspase-1 maturation in primary human RPE cells at
24 hours after Alu administration (top, lane 2, lower band),
which is blocked with co-treatment with azidothymidine
(AZT), cordycepin, and abacavir (ABC) (50-100 uM; Lanes
3-8). Again, the loading control vinculin is shown on the
bottom.
In certain embodiments, the present disclosure provides
that d4T inhibits inflanmiasome activation by LPS/ATP. As
such, FIG. 8 provides a gel showing that primary human
RPE cells treated with LPS/ATP, a classic inflanmiasome
activator, exhibit increased Casp-1 activation, and phosphorylation ofIRAK4, which is also a marker of inflanmiasome
signaling via the cell surface receptor adaptor protein
MyD88. Moreover, as shown in FIG. 8, d4T (25/100 uM)
blocks Casp-1 activation and IRAK4 phosphorylation
induced by LPS/ATP. The loading control in FIG. 8 is
vinculin. Furthermore, as shown, LPS and ATP activate the
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NLRP3 inflammasome only in combination, thus treatment
with one or the other alone is useful as a control for this
experiment.
The present disclosure further provides that, in exemplary
embodiments, d4T and other NRTis reduce inflammasome
activation by LPS/ATP. As presented in FIG. 9, d4T, 3TC,
and cordycepin (at 100 uM), all di-deoxy nucleoside reverse
transcriptase inhibitors, inhibit Caspase-1 activation (active
p20 band, top) and IL-18 maturation (bottom) induced by
LPS/ATP. To produce FIG. 9, cell culture supernatants were
collected after (i) no treatment, (ii) LPS treatment, or (iii)
LPS/ATP treatment of mouse bone marrow-derived macrophages and run on Western blotting probing with antibodies
for Caspase-1 and IL-18.
In some embodiments of the present disclosure, d4T
inhibits nigericin-induced inflammasome activation. Per
FIG. 10, d4T (100, 250 uM) inhibits IL-1 beta maturation
(top, 18 and 22 kDa forms) and Caspase-1 activation (active
p20 band, bottom) induced by nigericin. Cell culture supernatants were collected after (i) no treatment, (ii) LPS treatment, or (iii) LPS/nigericin treatment of mouse bone marrow-derived macrophages, and run on Western blotting
probing with antibodies for IL-1 beta and Caspase-1. FIG.
10 shows the results of these efforts.
Additionally, in some embodiments, d4T does not inhibit
IL-1 beta secretion from PMA-differentiated THP-1 monocytes induced by MSU. Human THP-1 monocytes were
differentiated into macrophages with PMA. As shown in
FIG. 11, treatment with monosodium urate (MSU), a known
inflammasome activator, increased IL-1 beta secretion compared to non-treated cells, whereas d4T co-administration at
a range of doses (25-1000 uM) did not significantly affect
IL-1 beta secretion. Further, d4 T does not block MSUinduced IL-1 beta secretion as determined by ELISA (n=34).
In certain embodiments, d4T and other nucleoside reverse
transcriptase inhibitors do not inhibit IL-1 beta secretion
from PMA-differentiated THP-1 monocytes induced by
MSU. To illustrate this, human THP-1 monocytes were
differentiated into macrophages with PMA. Treatment with
MSU increased IL-1 beta secretion compared to non-treated
cells. (FIG. 12) Meanwhile d4T, 3TC, or cordycepin (all are
di-deoxy nucleotide analogs) co-administration at a range of
doses (25-1000 uM) did not significantly affect IL-1 beta
secretion, as shown in FIG. 12.
Next, in some embodiments, d4T reduces NLRP3 priming
induced by Alu RNA. Indeed, as provided in the bar graph
of FIG. 13, Alu RNA transfection increases NLRP3 mRNA
levels in primary human RPE cells at 16 hours, an event
termed "priming" (Y-axis) compared to mock (transfection
reagent alone). This effect is blunted by co-administration of
d4T (100 uM) and normalized to 18S RNA control.
Furthermore, in exemplary embodiments of the present
disclosure, d4 T reduces IL-1 beta priming induced by Alu
RNA. FIG. 14 illustrates that Alu RNA transfection
increases IL-1 beta mRNA levels in primary human RPE
cells at 24 hours, an event termed "priming", (Y-axis)
compared to mock (transfection reagent alone). This effect is
blunted by co-administration of d4T (100 uM) and normalized to 18S RNA control.
Meanwhile, in some embodiments, d4T reduces mitochondrial ROS caused by Alu expression. FIG. 15 demonstrates that enforced expression of Alu (pAluA) causes
increased mitochondrial reactive oxygen species (mtROS),
as detected by MitoSox assay. In order to produce FIG. 15,
primary human RPE cells were incubated with Alu expressing plasmid or control plasmid (pUC19) with or without

d4T. After 15 hours cells were co-stained for mtROS (red)
and for cell count, nuclei (blue; Hoechst DNA stain). Cells
in the pAluA group exhibited greater mtROS staining (red)
compared to pUC19 control, an effect that is reduced in
pAluA+d4T treated cells.
And in further embodiments, d4T does not inhibit ATP
release induced by Alu RNA. (FIG. 16) Primary human RPE
cells treated with Alu RNA for the times indicated release
ATP. To provide FIG. 16, cell culture supernatant was
collected from mock or Alu RNA treated cells, with or
without d4T. ATP was detected using an ATP-dependent
luciferase assay. And, notably, d4T did not affect ATP
release.
In certain embodiments, d4T reduces ATP-induced cell
permeability to Yo-Prol (P2X7 receptor assay), as shown in
FIG. 17. To prepare FIG. 17, THP-1 cells differentiated into
macrophages by PMA allowed entry of the large fluorescent
dye Yo-Pro 1, in an assay for P2X7 receptor activity. It was
observed that d4T dose-dependently reduced Yo-Pro entry
induced by ATP, determined by an area-scan fluorescent
measurement in a 96 well microplate reader. Indeed, FIG. 17
provides the results of the fluorescence measurement in
relative fluorescence units (RFU, y-axis).
Furthermore, it has been shown that d4T reduces extracellular potassium levels that increase after Alu RNA transfection. (FIG. 18) Indeed, cell culture potassium levels
increase in primary human RPE cells treated with Alu RNA
for 6 hours, an effect that is reduced by d4T co-administration. For FIG. 18, potassium levels were determined in cell
culture supernatants spectrophotometrically using a potassium-dependent pyruvate kinase assay.
Next, in some embodiments, d4T blocks bzATP-induced
cell permeability to Yo-Prol (P2X7 receptor assay), as
shown in FIG. 19. d4T blocked YO-PRO-1 iodide entry in
HEK293 cells stably expressing the human P2X7 receptor
stimulated with the P2X7-selective agonist bzATP. Cells
were pre-incubated with d4T for 30 minutes prior to addition
of bzATP/YO-PRO, and fluorescence at 485/515 nm measured at t=30 minutes.
Moreover, d4T blocks Alu-induced RPE degeneration and
Caspase-1 activation independent of reverse transcriptase
inhibition.
In some embodiments, the present disclosure is directed
to a compound having the structure(s) provided in FIG. 20.
FIG. 20 includes a chemical structure of methoxy-d4T
(me-d4T) and of d4T. As shown in FIG. 20, a single
substitution of the ribose 5' hydroxyl group with a methoxy
group (circled) has been designed by the inventors of the
present disclosure to prevent d4T phosphorylation. Accordingly, in some embodiments, the present disclosure is
directed to a compound comprising a single substitution of
a ribose 5' hydroxyl group with a methoxy group. And, in
some embodiments, the present disclosure provides compounds comprising a methoxy group in place of a ribose 5'
hydroxyl group for preventing phosphorylation, such as d4T
phosphorylation.
The present disclosure further provides the results of
additional experiments in FIG. 21-FIG. 23. Indeed, FIG. 21
is a Western blot of Caspase-1 activation (p20 subunit) in
primary human RPE cells transfected with Alu RNA±med4T; FIG. 22 shows cells, wherein unmodified d4T, but not
me-d4 T, blocks replication of a GFP-expressing lentivirus in
HeLa cells; and FIG. 23 provides a graph illustrating that
unmodified d4T, but not me-d4T, reduces mtDNA levels
(normalized to chromosomal DNA exon-intron junction
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sequence) in primary mouse RPE cells as determined by
real-time quantitative PCR. n=4, *p<0.05 by Student's
t-test.
In some embodiments, it has been shown that Me-d4T
(intraperitoneal injection) prevents Alu-induced RPE degeneration in mice. FIG. 24, top row, provides flat mounts
stained for zonula occludens-1 (ZO-1; red), bottom row.
Degeneration is outlined if FIG. 24 by blue arrowheads.
Representative images of n=4 are shown.
Meanwhile, FIG. 25 provides a schematic overview of
me-d4T synthesis, and FIG. 26 is an HPLC chromatogram
of me-d4T (peak #6) final product, >97% purity. And FIG.
27 is a lH NMR spectroscopy of me-d4T final product,
wherein the chemical shifts are consistent with the structure,
and FIG. 28 provides the results of liquid chromatography/
mass spectrometry of me-d4T final product, m/z ratio consistent with the structure.
FIG. 29, FIG. 30 and FIG. 31 provide for methoxy
variants of nucleoside analogs. Specifically, FIG. 29 shows
the chemical structure of 3TC (2'3' dideoxycytidine); FIG.
30 provides the chemical structure of AZT (3'-azido-2',3'dideoxythymidine); and FIG. 31 shows the chemical structure of ABC (cyclopropylaminopurinylcyclopentene). In
each of FIGS. 29-31, the methoxy variation (O-methyl
group) of nucleoside analog is circled. Further, FIG. 32
shows a cell permeant variant of d4T (IC-d4T), where "n"
group is equal to 11. Derivatives include cell permeant
variants of 3TC, AZT, ABC, where the nucleobase group
(circled) may be replaced, in various embodiments, by 3 TC,
AZT, ABC, or methoxy-variants of d4T, 3TC, AZT, ABC
(FIG. 29-31), or derivatives thereof.
Meanwhile, FIG. 33 provides the chemical structure of an
exemplary NRTI according to the present disclosure.
In certain embodiments, the present disclosure provides
that NRTis block Alu-induced RPE degeneration and/or
Caspase-1 activation. For example, FIG. 34 shows a Western
blot of Caspase-1 activation (p20 subunit) and IRAK4
phosphorylation in primary human RPE cells transfected
with Alu RNA±d4T. FIG. 35 is a Western blot ofCaspase-1
activation in human RPE cells transfected with Alu
RNA±NRTis (3TC, AZT, ABC). FIG. 36 shows that pAlu
causes RPE degeneration, which is prevented by oral administration of d4T, and FIG. 37 shows that pAlu causes RPE
degeneration, which is prevented by intraperitoneal administration of AZT. FIG. 36 and FIG. 37 include fundus
photographs: top row; flat mounts stained for zonula
occludens-1 (ZO-1; red), bottom row. Degeneration is outlined by blue arrowheads. Scale bars, 50 µm.
FIGS. 38-41 illustrate that NRTis block LPS/ATP-induced inflammasome activation. FIGS. 38 and 39 show that
d4T blocked Caspase-1 (FIG. 38) and IL-1 beta (FIG. 39)
activation in LPS/ATP treated primary mouse bone marrowderived macrophages as determined by western blot of cell
culture media and lysate. Moreover, FIG. 40 presents chromatograms showing that Raji TK- cells, but not Raji TKcells, phosphorylate AZT to AZT-triphosphate (AZT-TP) as
determined by liquid chromatography-mass spectrometry
(LC-MS). And FIG. 41 shows that AZT blocks IL-1 beta
activation by LPS/ATP in both Raji TK- and TK+ cells as
determined by western blot of cell lysates. Representative
images ofn=3-4 experiments are provided in each of FIGS.
38-41.
In some embodiments, the present disclosure provides
that NRTis selectively block P2X7 pore function and P2X7driven models of graft rejection and sterile liver inflammation, as shown in FIGS. 42-43. FIG. 42 is a bar graph
illustrating that d4 T does not block Alu-induced ATP release

from primary human RPE cells (n=4). Meanwhile, FIG. 43
is a graph illustration showing that NRTis selectively block
P2X7 pore function and P2X7-driven models of graft rejection and sterile liver inflammation, providing a graph of the
fluorescence (% of bzATP) over time (minutes).
And in certain exemplary embodiments, the present disclosure provides that d4T blocks Caspase-1 activation without reducing Alu RNA levels. Accordingly, FIG. 44 provides
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Western blot of Caspase-1 activation (p20 subunit) and
IRAK4 phosphorylation in primary mouse RPE cells transfected with Alu RNA±d4T. And FIG. 45 presents a Northern
blot of biotin-DTP-labeled Alu RNA-transfected primary
human RPE cells. Notably, in FIG. 45, d4T did not reduce
Alu RNA levels (normalized to u6 RNA).
Next, FIGS. 46-47 provide LC-MS/MS spectra of AZTtriphosphate (AZT-TP, target compound; FIG. 46) andAZUtriphosphate (AZU-TP, internal standard; FIG. 47). And
FIGS. 48-49 show the chromatographic separation of Raji
TK- cells spiked withAZT-TP (FIG. 48) andAZU-TP (FIG.
49) with MS spectra (insets) to confirm identity of designated peaks.
FIG. 50 is a standard curve of AZT-TP standards (black
circle). Raji TK+ samples treated with AZT producedAZTTP (white triangles), whereas AZT-TP was not detectable in
Raji TK- cells treated with AZT. FIG. 50 is representative of
two experiments.
FIGS. 51-54 show that, in some exemplary embodiments,
P2X7-dependent pore function mediates Alu-induced
Caspase-1 activation. Indeed, FIG. 51 is a Western blot of
Caspase-1 activation (p20 subunit) in primary human RPE
cells transfected with Alu RNA, with short peptide
(Panxl 10 ), which blocks P2X7 pore function but not cation
flux (vs. scrambled peptide: Ser Panxl 10 ); FIG. 52 is a
Western blot of Caspase-1 activation (p20 subunit) in primary human RPE cells transfected with Alu RNA, with
calmidazolium (FIG. 32 provides the chemical structure of
IC- and EC-d4T used), which blocks P2X7 cation flux but
not pore function; and FIG. 53 is a Western blot of
Caspase-1 activation (p20 subunit) in primary human RPE
cells transfected with Alu RNA, with cell permeable (IC),
cell-impermeable (EC), or unmodified (no tag) d4T. Furthermore, FIG. 54 shows that d4T prevents pAlu-induced
mitochondrial ROS generation in primary human RPE cells.
In FIG. 54, mitochondrial reactive oxygen species (ROS)
were visualized with MitoSox (Red) and cell nuclei with
Hoechst (Blue).
One of ordinary skill in the art will recognize that additional embodiments or implementations are possible without
departing from the teachings of the present disclosure or the
scope of the claims which follow. This detailed description,
and particularly the specific details of the exemplary
embodiments and implementations disclosed herein, is
given primarily for clarity of understanding, and no unnecessary limitations are to be understood therefrom, for modifications will become obvious to those skilled in the art upon
reading this disclosure and may be made without departing
from the spirit or scope of the claimed invention.
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All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication,
patent, or patent application was specifically and individually indicated to be incorporated by reference.
It will be understood that various details of the presently
disclosed subject matter can be changed without departing
from the scope of the subject matter disclosed herein.
Furthermore, the foregoing description is for the purpose of
illustration only, and not for the purpose of limitation.
What is claimed is:
1. A method of treating a condition selected from Parkinson's disease, Alzheimer's disease, and multiple sclerosis
comprising administering to a subject in need thereof a
compound selected from:
(i) a compound having the structure of formula I
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or a pharmaceutically acceptable salt thereof;
(ii) a compound having the structure of formula II
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(iii) a compound having the structure of formula III, or a
pharmaceutically acceptable salt thereof;

2. The method of claim 1, wherein the compound is

selected from:
(i) the compound having the structure of formula I
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(iv) a compound having the structure of formula IV,
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or a pharmaceutically acceptable salt thereof;
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(ii) the compound having the structure of formula II
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wherein n is 10 to 20;
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(v) a compound having the structure of formula V

(V)
45

50

(iii) the compound having the structure of formula III, or
a pharmaceutically acceptable salt thereof;
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(vi) stavudine (d4T);
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(vii) lamivudine (3TC);
(viii) cordycepin;
(ix) azidothymidine (AZT);
(x) abacavir (ABC); and
(xi) a combination thereof.
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(iv) the compound having the structure of formula IV,

(ii) the compound having the structure of formula II
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and
(iii) a compound having the structure of formula V
wherein n is 10 to 20;
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(v) a compound having the structure of formula V
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and
(iv) a combination thereof.

(vi) a combination thereof.

5. The method of claim 1, wherein the compound 1s

3. The method of claim 1, wherein n is 11.

selected from:

4. The method of claim 1, wherein the compound is 45

(i) the compound having the structure of formula

selected from:
(i) the compound having the structure of formula
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or a pharmaceutically acceptable salt thereof;

or a pharmaceutically acceptable salt thereof;
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(ii) a compound having the structure of formula V

7. The method of claim 1, wherein the compound is the

compound having the structure of formula II:
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8. The method of claim 1, wherein the compound is the
compound having the structure of formula V:
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(iii) a combination thereof.
6. The method of claim 1, wherein the compound is a
compound having the structure of formula I
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or a pharmaceutically acceptable salt thereof.

9. The method of claim 1, wherein the compound 1s
selected from
(vi) stavudine (d4T);
(vii) lamivudine (3TC);
(viii) cordycepin;
(ix) azidothymidine (AZT);
(x) abacavir (ABC); and
(xi) a combination thereof.
10. The method of claim 1, wherein the method comprises
administering a composition comprising the compound and
a pharmaceutically acceptable carrier.
11. The method of claim 1, wherein the condition is
Parkinson's disease.
12. The method of claim 1, wherein the condition is
Alzheimer's disease.
13. The method of claim 1, wherein the condition is
multiple sclerosis.
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